Introduction
A poptotic cell death is a regulated pathway that is required for homeostasis of organ function. However, malignant transformation of cells can occur via defects in the apoptotic pathway or overexpressed regulatory factors that prevent apoptosis [1] . These defects can also lead to treatment resistance [2] . Thus, a number of therapies targeted at either correcting deficiencies in or promoting apoptosis are currently in development to improve the treatment of cancer. Such therapies include death receptor 5 (DR5) agonists [3, 4] , inhibitors of Bcl-2 [5] , SMAC mimetics [6, 7] , and inhibitor of apoptosis protein (IAP) antagonists [8, 9] , all of which effectively treat tumors in preclinical models by activating the effector caspases caspase-3 and caspase-7. Thus, methods that can detect apoptotic activation, and specifically caspase-3 activity, may be useful markers of treatment response for targeted apoptosis treatments.
Available methods for quantifying apoptosis require tissue sampling to assess the degree of apoptosis present. Noninvasive imaging measures of apoptosis would therefore be helpful for demonstrating the efficacy of apoptosisinducing treatments without requiring tissue sampling. Several different imaging approaches have been developed to image apoptosis, including radiolabeled annexin V that targets phosphatidylserine (PS) residues exposed externally during apoptosis [10] [11] [12] and a cation-based tracer that is retained in normal cells but is released by mitochondrial membrane voltage changes induced during apoptosis [13] . However, PS residues are also exposed during necrosis, and decreases in tracer uptake as a result of treatment may be more difficult to use clinically than tracers that specifically increase binding as a result of apoptosis. ML-10 is another small molecule tracer for imaging apoptosis [14] [15] [16] , but how it specifically targets apoptotic cells is unknown.
Radiolabeled isatin sulfonamides are reversible competitive caspase-3 inhibitors that have been developed as positron emission tomography (PET) tracers for imaging caspase-3 activation [17] [18] [19] [20] [21] [22] [23] [24] [25] . These have been used successfully to image apoptotic treatment responses in mouse models of cancer [20, 26] . Given their specific binding to caspase-3 (and to caspase-7 to a lesser extent), these analogs represent the only class of compounds that target this specific effector of apoptosis. Therefore, this class of tracers could potentially be used for measuring the response of therapies that target caspase-3-mediated apoptosis for cancer treatment.
For this study, we hypothesized that isatin sulfonamide analogs would be able to image caspase-3 activation in tumors treated with a DR5-targeted antibody. We first evaluated the in vitro characteristics and in vivo metabolism of several analogs. We then evaluated the ability of the most promising of these candidates, [ 18 F]WC-4-116, to detect caspase-3 activation in a mouse model of tumor apoptosis induced by DR5-targeting antibodies. Given that all caspase-3 inhibitors also bind to caspase-7 to a lesser extent, we will refer to these tracers as caspase-3-targeted with the understanding that they also target caspase-7.
Materials and Methods

Precursor Synthesis and Radiolabeling
The structures and affinities for caspase-3 of all the caspase-3 targeted tracers used for these studies are listed in Table 1 . The precursors for all tracers were synthesized as described previously [19, 27] radiosynthesized via a two-step procedure starting from radiolabeling of 4 and followed by reaction with the corresponding phenol precursor 5 or 6 (Fig. 1) . The radiolabeling process took 90 min for the click synthesis and 150 min for the two-step procedure, after which the tracers were immediately used for the experiments as detailed below. The IC50 and EC50 values for all tracers were previously published [19, 28] except for the EC50 for WC-4-36, which was determined in HeLa cells treated with staurosporine as previously described [19] (Table 1) . The Supplement includes additional details regarding precursor synthesis and radiolabeling.
Reagents for Cell Culture and Animal Studies
The institutional Animal Studies Committee approved all animal studies. The EL4 murine lymphoma cell line (ATCC) and Colo205 cells (gifts from Amgen and Novartis) were cultured in either Dulbecco's Modified Eagle Medium (DMEM) or RPMI-1640, respectively, with 10 % heat-inactivated fetal calf serum (FCS), penicillin (100 U/ml), streptomycin (100 μg/ml), and glutamine (2 mM). Etoposide was obtained from Belford Laboratories. DR5-targeted antibodies M413 and LCR211 were also generous gifts from Amgen and Novartis, respectively. Cleaved caspase-3-targeting rabbit anti-mouse IgG antibody was obtained from Cell Signaling.
Cell Uptake Assay
A previously published model for inducing apoptosis in EL4 cells was employed for in vitro studies [29] . EL4 cells (1×10 7 18 F]WC-4-116 uptake was also determined in etoposide-treated EL4 cells with and without Q-VD-OPh, a pan-caspase inhibitor (25 μM added at the same time as etoposide). Cells were removed in 0.5 ml aliquots of media at 5, 30, and 60 min after tracer addition, washed twice with PBS, and measured in a gamma counter. Cells were then counted by hemacytometer with trypan blue to determine cell viability. The tracer uptake was then expressed as the % cell activity normalized to the number of viable cells. For the tracer comparison studies, the protein samples were pooled for each treatment group to assess caspase-3 activity and thus were not analyzed statistically. Caspase-3 activity was determined for each individual cell pellet in the Q-VD-OPh studies. The individual measurements from each time point for tracer uptake and caspase-3 activity in the Q-VD-OPh studies did not vary with time after tracer injection; thus, they were summarized as the mean % cell activity and AFU/min/μg protein for statistical analysis. The fold increase for each tracer was determined as the ratio of the mean % cell activity for the treated group divided by that for the untreated control group. All studies were performed in duplicate.
Metabolism Studies
Female Balb/c mice (8-10 weeks, 20 g) were injected with 7.4 MBq (200 μCi) of each tracer and then sacrificed at either 5 or 30 min after tracer injection. Whole blood was obtained by heart puncture, placed in heparinized tubes, and centrifuged to separate cells from plasma. The liver (0.5 g) was also removed and immediately frozen on dry ice. Plasma (400 μl) or the liver sample was mixed or homogenized with a 1:1 acetonitrile:methanol solution and then centrifuged. The supernatant was then analyzed by thin layer chromatography (TLC) using silica gel TLC in 10 % methanol/dichloromethane. The parent was confirmed by codevelopment with cold standard. All of the blood and liver fractions generated as a result of tissue processing were counted in a gamma counter (Beckman Gamma 6000). These measurements were then used to determine the percent of activity extracted into the supernatants used for TLC analysis. The percent of parent compound was calculated by the counts of parent over all counts, Biodistribution Studies The following organs were harvested, blotted to remove excess blood, weighed, and counted in a gamma counter to determine the % injected dose per gram of tissue (% ID/g): tumors, blood, bone, brain, fat, heart, kidney, liver, lung, muscle, spleen, thymus, and tail. The tumors were additionally flash frozen on dry ice immediately after harvest, counted while frozen, and then stored at −80°C for later assessment of caspase-3 enzyme activity. Any animal with 10 % or more of the injected dose in the tail was excluded from the analysis.
Animal Dosing for Biodistribution and MicroPET Studies
MicroPET Imaging Studies
Colo205 tumor-bearing mice treated with M413 or PBS (N=6 per group) underwent a 60-min dynamic scan on Inveon PET/CT (Siemens) or Focus 220 PET scanners (Siemens/CTI) after injection of 10±1.4 MBq (271±39 μCi) of [
18 F]WC-4-116, preceded or followed by a microCT scan on the Inveon scanner. The mice were sacrificed after imaging and tumors removed to verify caspase-3 activity by the enzyme assay (N=4 per group) or immunohistochemical (IHC) staining (N=2 per group). The microPET and microCT images were co-registered using Integrated Research 
Immunohistochemical Staining
Tumors were fixed in 10 % formalin and then embedded in paraffin. Five micron tumor sections were then deparaffinized through xylene and ethanol washes, rinsed with distilled water, and boiled in a rice cooker for 45 min in a 10 mM (pH 6.0) sodium citrate buffer for epitope retrieval. Sections were stained for cleaved caspase-3.
Caspase-3 Enzyme Activity Assay
Caspase-3 enzyme activity was quantified as arbitrary fluorescence units per min per μg protein (AFU/min/μg protein) as previously described [17, 18, 31] 
Statistical Analysis
Data are expressed as the mean±standard deviation (SD). One-way analysis of variance (ANOVA) (JMP, SAS, Cary NC) compared the log-transformed least square means for % viable cell tracer uptake and AFU/min/μg protein (caspase-3 enzyme activity) for the in vitro cell uptake experiments. Two-way ANOVA (time by treatment) also assessed for differences in the log-transformed least square means for the % ID/g and AFU/min/μg protein for the biodistribution studies, with tumors separated based on high or low caspase-3 activity since we intended to demonstrate that [
18 F]WC-4-116 uptake reflects in vivo caspase-3 activity. Therefore, a threshold of G0.05 for the mean AFU/ug/min of both tumors of each mouse was used to group mice into "low" vs "high" caspase-3 activity groups. One-tailed Student's t test with post hoc Bonferroni correction for multiple comparisons assessed for differences between M413-treated and untreated control mice in the microPET-determined % ID/cc at 30 min, the peak activity in the time-activity curve, % ID/cc at 30 min normalized to peak activity, and the AUC 40-60 min after log transformation. Student's t test also assessed for differences in AFU/min/μg protein in microPETimaged mice. PG0.05 determined statistical significance. Figure 2 summarizes the cell uptake study results. The tracer uptake (% cell activity) and caspase-3 activity (AFU/min/μg protein) for all time points with each tracer were averaged together as neither of these parameters changed significantly with time in vitro. 30 and 60 min. When comparing tumor to organ ratios, the tumor:fat and tumor:muscle ratios were difficult to interpret given the wide variability in the measured activity in both fat and muscle. The tumor:blood ratios appeared to increase over time, most likely due to the rapid clearance of the tracer from the blood relative the tumors. Figure 3 summarizes the tracer uptake and caspase-3 enzyme activity for the biodistribution studies assessing 18 F]WC-4-116 biodistribution studies, one mouse in the 5 min untreated group was excluded due to a poor tail vein injection. One mouse without antibody treatment in the 30 min group had high caspase-3 activity in both tumors (mean 0.19 AFU/min/ μg protein), while two mice (4 tumors) treated with M413 had low tumoral caspase-3 activity (0.011 ± 0.001 AFU/min/μg protein). One mouse in the 30 min high caspase-3 group had only one tumor. [ 18 F]WC-4-116 uptake was significantly higher in tumors at 30 min but not at 60 min, suggesting rapid washout of the tracer from the treated tumors (Fig. 3) . The tumors that demonstrated increased caspase-3 enzyme activity also had increased [ 18 F]WC-4-116 uptake. In the [ 18 F]ICMT-18 study, one treated mouse at 5 min and two mice at 60 min had low tumoral caspase-3 activity (mean 0.007 and 0.008±0.004 AFU/min/μg protein, respectively). [ 18 F]ICMT-18 uptake did not differ significantly among tumors with high or low caspase-3 enzyme activity, especially at 30 min where the number of mice remained balanced in the high and low caspase-3 groups. The 30 min high caspase-3 activity group contained one high outlier (2.2 % ID/g) with relatively low caspase-3 activity compared to the rest of the group (0.07 AFU/min/μg protein) that was included in the analysis. Without this outlier, the mean % ID/g for the high caspase-3 activity group (1.1 ± 0.1 % ID/g) at 30 min was only 1.1 times higher than that of the low caspase-3 activity group (Fig. 3) .
Results
Cell Uptake Assays
MicroPET Imaging Studies
MicroPET imaging with [ (Fig. 4) , even after normalization for the peak % ID/cc in the time-activity curve (untreated=0.34±0.08, treated=0.45±0.18, unitless, onetailed p=0.011). The area under the curve (AUC) for [ 2.3±0.6, treated=2.8±0.8 % ID/cc, one-tailed p=0.07). Treatment increased either caspase-3 enzyme activity or cleaved caspase-3 immunohistochemical staining in all tumors removed from treated mice (Fig. 5) . 18 F] ICMT-18 biodistribution study, a high outlier (2.2 % ID/g) in the 30 min high caspase-3 activity group was included in the analysis and in the graph. The fold-change between high and low caspase-3 activity groups was 1.1 without this high outlier. *pG0.05.
Discussion
Our data support using radiolabeled isatins as markers of caspase-3 activation. Of the tracers evaluated, [ 18 F]WC-4-116 had the best characteristics for imaging treatmentinduced apoptosis in tumors. In cell uptake studies, where uptake of each tracer should be optimized, [ 18 F]WC-4-116 demonstrated the greatest fold increase as a result of caspase-3 activation, in line with its improved caspase-3 inhibition potency in whole cell assays compared to the other tracers as shown in Table 1 ]WC-4-36 uptake also appeared to reflect caspase-3 activation in vitro, but their characteristics were less optimal for body tumor imaging. The hydrophilic pegylation added to these compounds improved their ability to diffuse into cells as previously published [19] . However, the fold change in uptake for these compounds after caspase-3 activation was lower than that of activity in mice treated with DR5-targeted antibodies. Thus, our data, along with previously published data on the related tracers [
18 F]ICMT-11 [20] and [ 18 F]WC-II-89 [17] , support the ability of these compounds to measure caspase-3 activation specifically in vivo.
We originally reported the synthesis and biological evaluation of the first generation of radiolabeled isatins for imaging in vivo caspase-3 activation [17, 18, 21, 32] . In models of liver apoptosis, we demonstrated that the best of our first-generation tracers, [ 18 F]WC-II-89, was specific but was not as sensitive for in vivo caspase-3 imaging as we had expected based on the in vitro data. Therefore, we investigated additional chemical modifications to the core isatin structure and also developed a whole cell assay to better assess the cell penetration of these compounds [19] 18 F]ICMT-11 uptake are generally lower than the increases in caspase-3 enzyme activity in both in vitro and in vivo studies [26, 33] . Since these tracers are competitive inhibitors of caspase-3, uptake is related to direct binding of the tracer to activated caspase-3 without the benefit of a specific trapping mechanism to amplify the signal as in the case of the fluorescent cleavable substrate used in the enzyme activity assay. Thus, when comparing the uptake of these tracers with the substrate-based caspase-3 enzyme assay, we would expect the tracer uptake to be lower given the absence of a signal amplification mechanism for these tracers. We also attempted to optimize diffusion into cells to improve uptake by pegylating the third-generation analogs, but we observed in both the cell uptake assays and biodistribution studies that the improved cell penetration of [ 18 F]WC-4-35 led to increased nonspecific tracer retention. In contrast, [ 18 F] WC-4-116 and [
18 F]ICMT-11 provided better contrast on the microPET images given their more rapid washout kinetics in normal tissues. Assessment in humans will best confirm whether the dynamic range of uptake for these tracers will be adequate for clinical use.
In 
